Arrowhead Pharmaceuticals, Inc. today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being ...
Ahmedabad: The two-day national conference (NATCON) 2025 of the Indian Medical Association (IMA) in the city concluded on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback